Consultant Clinical Oncologist


Dr Nicola Dallas

Consultant in Reading since – 2011

Where qualified

I graduated from the University of Birmingham Medical School in 1998 and became a member of the Royal College of Physicians in 2001. I completed my oncology training in Oxford becoming a Fellow of the Royal College of Radiologists in 2007. I was appointed as a Consultant Clinical Oncologist at the Berkshire Cancer Centre, Royal Berkshire Hospital in Reading in 2011

Clinical Involvement

I now practice at Dunedin and GenesisCare Oncology Centre Windsor.

I specialise in the treatment of prostate, bladder, kidney and testicular cancers, head and neck and thyroid cancers. I have a particular interest in technical radiotherapy techniques including IMRT, dynamic arc IMRT and IGRT.

I am a principle investigator and sub investigator for a number of phase 3 clinical trials in urological and head and neck cancer including PATHOS, a head and neck radiotherapy trial looking at reducing the intensity of treatment in selected cases.

At the Berkshire Cancer Centre I am the Clinical Governance and Audit Lead as well as an educational supervisor for specialist oncology trainees.


I have published and presented work on prostate brachytherapy, testicular tumours and head and neck cancer.


No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer. 

H De La Pena, A Sharma, C Glicksman, J Joseph, M Subesinghe, Z Triall, C Verrill, M Sullivan, J Redgwll, E Bataillard, E Pintus, N Dallas, A Gogbashian, MTuthill, A Protheroe, M Hall.

Eur J Cancer 2017 84: 354-359

Establishging a large prospective clinical cohort in people with head and neck cancer as a biomedical resourse: head and neck 5000.

A R Ness, A Waylen, K Hurley, M Jeffreys, C Penfold, M Pring, S Leary, C Allmark, S Toms, S Ring, T J Peters, W Hollingworth, H Worthington, C Nutting, S Fisher, S N Rogers, S J Thomas, The Head and Neck Study 5000 Study Team.

BMc Cancer 2014;14:973

The results of real time brachytherapy for the management of low and intermediate risk prostate cancer in patients with prostate volumes up to 100ml. 

N L Dallas, P R Malone, A Jones, A Dogcart, K J McConway, P B Rogers.

BJU Int 2012; 110:383-390

Author of Throid Cancer chapter in Challenging Concepts in Oncology 2015.


I am an investor in the Genesis Care, Windsor, Diagnostic and Oncology Centre.

I have accepted sponsorship from drug companies to attend international oncology meetings.  I have no financial relationship with any pharmaceutical company.